Incannex Healthcare LTD IXHL
We take great care to ensure that the data presented and summarized in this overview for Incannex Healthcare Ltd is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in IXHL
Top Purchases
Top Sells
About IXHL
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
Insider Transactions at IXHL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 23
2024
|
Luigi M. Barbato Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,476
+50.0%
|
-
|
|
Dec 21
2023
|
Troy Valentine Director |
BUY
Grant, award, or other acquisition
|
Direct |
670,000
+48.93%
|
-
|
|
Dec 21
2023
|
Joel Latham CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
1,340,000
+45.93%
|
-
|
|
Dec 21
2023
|
Peter Widdows Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+26.97%
|
-
|
|
Dec 21
2023
|
Robert Clark Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Dec 21
2023
|
George Anastassov Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+11.5%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 2.41M shares |
|---|